Acknowledgement
This study was partially supported by Taiwan's National Tsing Hua University (112F7MBBE1).
References
- Gross S, Jahn C, Cushman S, Bar C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications. J Mol Cell Cardiol 2020;144:47-53. https://doi.org/10.1016/j.yjmcc.2020.04.031
- Chitsike L, Duerksen-Hughes P. Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. Virol J 2021;18:154.
- Gui M, Song W, Zhou H, et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res 2017;27:119-29. https://doi.org/10.1038/cr.2016.152
- Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020;368:630-3. https://doi.org/10.1126/science.abb7269
- Trougakos IP, Terpos E, Alexopoulos H, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med 2022;28:542-54. https://doi.org/10.1016/j.molmed.2022.04.007
- Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clin Chem Lab Med 2020;58:1415-22. https://doi.org/10.1515/cclm-2020-0727
- Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181:894-904. https://doi.org/10.1016/j.cell.2020.03.045
- Ke Z, Oton J, Qu K, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 2020;588:498-502. https://doi.org/10.1038/s41586-020-2665-2
- Ismail AM, Elfiky AA. SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic. Signal Transduct Target Ther 2020;5:252.
- Ma J, Su D, Sun Y, et al. Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19. J Virol 2021;95:e00194-21.
- Yadav T, Srivastava N, Mishra G, et al. Recombinant vaccines for COVID-19. Hum Vaccin Immunother 2020;16:2905-12. https://doi.org/10.1080/21645515.2020.1820808
- Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-3. https://doi.org/10.1126/science.abb2507
- Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021;21:73-82. https://doi.org/10.1038/s41577-020-00480-0
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92. https://doi.org/10.1016/j.cell.2020.02.058
- Pack SM, Peters PJ. SARS-CoV-2-specific vaccine candidates; the contribution of structural vaccinology. Vaccines (Basel) 2022;10:236.
- Forthal DN. Functions of antibodies. Microbiol spectr 2014;2:1-17. https://doi.org/10.1128/microbiolspec.AID-0019-2014
- Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol 2018;18:46-61.
- Vivaldi G, Jolliffe DA, Faustini S, et al. Correlation between postvaccination anti-spike antibody titers and protection against breakthrough severe acute respiratory syndrome coronavirus 2 infection: a population-based longitudinal study. J Infect Dis 2022;226:1903-8. https://doi.org/10.1093/infdis/jiac321
- Goldblatt D, Fiore-Gartland A, Johnson M, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 2022;40:306-15. https://doi.org/10.1016/j.vaccine.2021.12.006
- Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS One 2020;15:e0244126. https://doi.org/10.1371/journal.pone.0244126
- Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021;39:4423-8. https://doi.org/10.1016/j.vaccine.2021.05.063
- Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43-50. https://doi.org/10.1126/science.abm3425
- Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. JAMA Netw Open 2022;5:e2231778.
- Barouch DH. COVID-19 vaccines: immunity, variants, boosters. N Engl J Med 2022;387:1011-20. https://doi.org/10.1056/NEJMra2206573
- Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med 2022;386:1603-14. https://doi.org/10.1056/NEJMoa2201688
- Hart JD, Chokephaibulkit K, Mayxay M, Ong-Lim AL, Saketa ST, Russell FM. COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron. Lancet Reg Health West Pac 2022;20:100404.
- Shen CJ, Lin YP, Hu SY, et al. Pilot study for immunogenicity of SARS-CoV-2 vaccine with seasonal influenza and pertussis vaccines in pregnant women. Vaccines (Basel) 2023;11:119.
- Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 2020;38:1073-8. https://doi.org/10.1038/s41587-020-0631-z
- Kolesov DE, Sinegubova MV, Dayanova LK, Dolzhikova IV, Vorobiev II, Orlova NA. Fast and accurate surrogate virus neutralization test based on antibody-mediated blocking of the interaction of ACE2 and SARS-CoV-2 spike protein RBD. Diagnostics (Basel) 2022;12:393.
- Kim D, Lee YJ. Vaccination strategies and transmission of COVID-19: evidence across advanced countries. J Health Econ 2022;82:102589.
- Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol 2022;94:2969-76. https://doi.org/10.1002/jmv.27697
- Wang L, Kainulainen MH, Jiang N, et al. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. Nat Commun 2022;13:4350.
- Burckhardt RM, Dennehy JJ, Poon LL, Saif LJ, Enquist LW. Are COVID-19 vaccine boosters needed?: the science behind boosters. J Virol 2022;96:e0197321.
- Atmar RL, Lyke KE, Deming ME, et al. Heterologous SARS-CoV-2 booster vaccinations: preliminary report. medRxiv [Preprint] 2021 Oct 15. https://doi.org/10.1101/2021.10.10.21264827
- Burki TK. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med 2022;10:e19.
- Granwehr BP. In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose. Ann Intern Med 2022;175:JC52.
- Stuart AS, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2022;399:36-49. https://doi.org/10.1016/S0140-6736(21)02718-5
- Montastruc JL, Biron P, Sommet A. NVX-Cov2373 Novavax COVID-19 vaccine: a further analysis of its efficacy using multiple modes of expression. Fundam Clin Pharmacol 2022;36:1125-7. https://doi.org/10.1111/fcp.12794
- Esposito M, Cocimano G, Vanaria F, Sessa F, Salerno M. Death from COVID-19 in a fully vaccinated subject: a complete autopsy report. Vaccines (Basel) 2023;11:142.